Guardant Health IPO
Guardant Health is a precision oncology company that develops blood-based liquid biopsy tests for cancer screening and treatment. The company's flagship products include Guardant360 for advanced cancer patients and Shield for colorectal cancer screening. Investors are interested in its position in the rapidly growing liquid biopsy market and potential to transform cancer diagnostics.
Key Facts
| Industry | Biotechnology |
| Founded | 2012 |
| Headquarters | Redwood City, CA |
| Employees | ~2,500 |
| Website | guardanthealth.com |
| Funding | Public company since 2018 IPO |
About Guardant Health
Guardant Health is a leading precision oncology company focused on liquid biopsy technology for cancer detection and monitoring. Their flagship products include Guardant360, a comprehensive genomic profiling test for advanced cancer patients, and Shield, a blood-based colorectal cancer screening test. The company's liquid biopsy platform analyzes circulating tumor DNA (ctDNA) in blood samples to detect cancer mutations and guide treatment decisions.
Guardant went public in 2018 and has established itself as a leader in the growing liquid biopsy market. Their technology offers a less invasive alternative to traditional tissue biopsies and enables real-time monitoring of treatment response and cancer evolution. The company has built extensive clinical evidence supporting their tests and secured coverage from major insurance payers, positioning them well as precision medicine becomes more integrated into standard cancer care.
IPO Status
Guardant Health went public in October 2018, raising $238 million in its IPO at $19 per share. The stock initially performed well, reflecting investor enthusiasm for the liquid biopsy technology and the company's partnerships with pharmaceutical companies for companion diagnostics. The company has continued to expand its product portfolio and clinical partnerships since going public. Guardant Health trades on NASDAQ under the ticker symbol GH and has established itself as a leader in the precision oncology space, though like many biotech stocks, it has experienced volatility based on clinical trial results and market conditions.
Competitors
Frequently Asked Questions
Does Guardant Health have a stock?
Yes, Guardant Health completed its IPO in October 2018. The company went public at $19 per share and raised $238 million.
When is the Guardant Health IPO date?
Guardant Health's IPO already occurred in October 2018. The company has been publicly traded on NASDAQ under the ticker GH since then.
How can I buy Guardant Health stock?
You can buy Guardant Health stock through any brokerage account using the ticker symbol GH. The stock trades on the NASDAQ exchange during regular market hours.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts